1551 related articles for article (PubMed ID: 17167397)
21. Economic impact of implementing decennial tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccination in adults in the United States.
Havers FP; Cho BH; Walker JW; Hariri S
Vaccine; 2020 Jan; 38(2):380-387. PubMed ID: 31676198
[TBL] [Abstract][Full Text] [Related]
22. How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine?
Halperin SA; Sweet L; Baxendale D; Neatby A; Rykers P; Smith B; Zelman M; Maus D; Lavigne P; Decker MD
Pediatr Infect Dis J; 2006 Mar; 25(3):195-200. PubMed ID: 16511379
[TBL] [Abstract][Full Text] [Related]
23. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials.
Weston WM; Friedland LR; Wu X; Howe B
Vaccine; 2012 Feb; 30(9):1721-8. PubMed ID: 22212127
[TBL] [Abstract][Full Text] [Related]
24. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults.
Pichichero ME; Rennels MB; Edwards KM; Blatter MM; Marshall GS; Bologa M; Wang E; Mills E
JAMA; 2005 Jun; 293(24):3003-11. PubMed ID: 15933223
[TBL] [Abstract][Full Text] [Related]
25. Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): a review of evidences and recommendations.
Bechini A; Tiscione E; Boccalini S; Levi M; Bonanni P
Vaccine; 2012 Jul; 30(35):5179-90. PubMed ID: 22709953
[TBL] [Abstract][Full Text] [Related]
26. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
Sirivichayakul C; Chanthavanich P; Limkittikul K; Siegrist CA; Wijagkanalan W; Chinwangso P; Petre J; Hong Thai P; Chauhan M; Viviani S
Hum Vaccin Immunother; 2017 Jan; 13(1):136-143. PubMed ID: 27686283
[TBL] [Abstract][Full Text] [Related]
27. Safety and immunogenicity of SIIPL Tdap, a new tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, in healthy subjects 4-65 years of age: A Phase II/III randomized, observer-blinded, active controlled, multicenter clinical study in Germany.
Aydin I; May M; Pisano F; Mpofu-Maetzig N; Grode L; Parekh S; Pujari P; Shewale S; Desai S; Sharma H; Rao H; Gautam M; Gairola S; Shaligram U
Vaccine; 2023 Nov; 41(46):6810-6819. PubMed ID: 37827966
[TBL] [Abstract][Full Text] [Related]
28. Pregnancy dose Tdap and postpartum cocooning to prevent infant pertussis: a decision analysis.
Terranella A; Asay GR; Messonnier ML; Clark TA; Liang JL
Pediatrics; 2013 Jun; 131(6):e1748-56. PubMed ID: 23713104
[TBL] [Abstract][Full Text] [Related]
29. Tetanus, diphtheria, pertussis vaccination coverage before, during, and after pregnancy - 16 States and New York City, 2011.
Ahluwalia IB; Ding H; D'Angelo D; Shealy KH; Singleton JA; Liang J; Rosenberg KD;
MMWR Morb Mortal Wkly Rep; 2015 May; 64(19):522-6. PubMed ID: 25996094
[TBL] [Abstract][Full Text] [Related]
30. Spotlight on Tdap₅ vaccine (Covaxis®) as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis: in children (aged ≥4 years), adolescents, and adults.
Scott LJ
Paediatr Drugs; 2011 Apr; 13(2):133-5. PubMed ID: 21351814
[TBL] [Abstract][Full Text] [Related]
31. Waning Tdap Effectiveness in Adolescents.
Klein NP; Bartlett J; Fireman B; Baxter R
Pediatrics; 2016 Mar; 137(3):e20153326. PubMed ID: 26908667
[TBL] [Abstract][Full Text] [Related]
32. Tetanus-diphtheria-acellular pertussis vaccination of adults in the USA.
Gidengil CA; Sandora TJ; Lee GM
Expert Rev Vaccines; 2008 Jul; 7(5):621-34. PubMed ID: 18564017
[TBL] [Abstract][Full Text] [Related]
33. Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five-dose series. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep; 2000 Nov; 49(RR-13):1-8. PubMed ID: 11106289
[TBL] [Abstract][Full Text] [Related]
34. Prevention of pertussis through adult vaccination.
Suryadevara M; Domachowske JB
Hum Vaccin Immunother; 2015; 11(7):1744-7. PubMed ID: 25912733
[TBL] [Abstract][Full Text] [Related]
35. Pertussis and patient safety: implementing Tdap vaccine recommendations in hospitals.
Tan TQ; Gerbie MV
Jt Comm J Qual Patient Saf; 2010 Apr; 36(4):173-8. PubMed ID: 20402374
[TBL] [Abstract][Full Text] [Related]
36. Pertussis vaccination in adult trauma patients: Are we missing an opportunity?
Yorkgitis BK; Timoney G; Salim A; Berg Pv; Goldberg AJ; Pathak A; Rappold JF
Surgery; 2015 Sep; 158(3):602-7. PubMed ID: 26032818
[TBL] [Abstract][Full Text] [Related]
37. Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults.
Brandon D; Kimmel M; Kuriyakose SO; Kostanyan L; Mesaros N
Vaccine; 2018 Oct; 36(42):6325-6333. PubMed ID: 30197282
[TBL] [Abstract][Full Text] [Related]
38. FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Sep; 60(37):1279-80. PubMed ID: 21937974
[TBL] [Abstract][Full Text] [Related]
39. Pertussis infection in the United States: role for vaccination of adolescents and adults.
Brooks DA; Clover R
J Am Board Fam Med; 2006; 19(6):603-11. PubMed ID: 17090793
[TBL] [Abstract][Full Text] [Related]
40. Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents.
Jackson ML; Yu O; Nelson JC; Nordin JD; Tartof SY; Klein NP; Donahue JG; Irving SA; Glanz JM; McNeil MM; Jackson LA
Pharmacoepidemiol Drug Saf; 2018 Aug; 27(8):921-925. PubMed ID: 29862604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
